Upcom­ing HERA call under EU4Health – Speed up the access to and uptake of an Mpox vac­cine

The Euro­pean Health Emer­gency Pre­pared­ness and Response Author­i­ty (HERA) has announced a new call for pro­pos­als under the EU4Health pro­gram, aimed at enhanc­ing Europe’s pre­pared­ness against health threats. This fund­ing oppor­tu­ni­ty focus­es on improved access to Mpox vac­cines. With a sig­nif­i­cant bud­get allo­ca­tion, this ini­tia­tive seeks to fos­ter inno­va­tion in med­ical coun­ter­mea­sures, strength­en pub­lic health strate­gies, and ensure faster respons­es to emerg­ing health crises.

Researchers, biotech firms, and health­care stake­hold­ers are encour­aged to sub­mit their pro­pos­als before the dead­line.

Speed up the access to and uptake of an Mpox vac­cine

Scope: This call for ten­ders aims to gen­er­ate sci­en­tif­ic evi­dence on the immune response to the MVA-BN vac­cine, focus­ing on the need and opti­mal tim­ing of boost­er dos­es through Phase II and/or III clin­i­cal tri­als, com­par­ing intra­der­mal and sub­cu­ta­neous admin­is­tra­tion, to inform pub­lic health strate­gies, EU poli­cies, and stock­pil­ing ini­tia­tives. This is an open pro­ce­dure with a max­i­mum con­tract dura­tion of 36 months.

Dead­line for receipt of requests to par­tic­i­pate: 21.4.2025 16:00 Europe/Brussels

Esti­mat­ed total val­ue: EUR 4.9Mio

Read more: Mpox Vac­cine Study F&Ts Appli­ca­tion Web­page

Source: Busi­ness Fin­land
Image: Tara Win­stead